CDMO Stock Forecast 2025-2026
Distance to CDMO Price Targets
CDMO Price Momentum
🤔 Considering Avid Bioservices (CDMO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest CDMO Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for CDMO. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CDMO Analyst Ratings
CDMO Price Target Range
Latest CDMO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CDMO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
(CDMO) Competitors
The following stocks are similar to Avid Bioservices based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(CDMO) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
(CDMO) Business Model
(CDMO) Latest News & Analysis
The Schall Law Firm is investigating Avid Bioservices (NASDAQ: CDMO) for potential breaches of fiduciary duty by its directors and management, raising concerns for investors.
Ongoing litigation could impact Avid Bioservices' stock price and investor confidence, signaling potential governance issues that may affect future performance and shareholder value.
The Schall Law Firm is investigating Avid Bioservices (NASDAQ:CDMO) for potential breaches of fiduciary duty by its directors and management on behalf of investors.
The investigation into Avid Bioservices could signal potential legal issues and governance concerns, impacting investor confidence and stock performance.
The Schall Law Firm is investigating Avid Bioservices (NASDAQ:CDMO) for potential breaches of fiduciary duty by its directors and management, which may affect investor interests.
The investigation into Avid Bioservices' board may indicate potential mismanagement or governance issues, impacting investor confidence and stock performance.
Avid Bioservices (NASDAQ: CDMO) launched a new corporate website to enhance user experience, featuring an updated brand identity and improved navigation for customers. Visit: www.avidbio.com.
Avid Bioservices' new website launch enhances its brand presence and user experience, potentially attracting more clients and driving growth, which can positively impact its stock performance.
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
1 month agoAvid Bioservices is expected to experience significant growth following new partnerships with GHO Capital and Ampersand Capital Partners.
Avid Bioservices' partnerships with GHO Capital and Ampersand Capital may drive expansion and enhance market competitiveness, potentially increasing stock value and investor returns.
Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners
1 month agoGHO Capital and Ampersand have completed the acquisition of Avid Bioservices, a CDMO focused on high-quality development and manufacturing services for biotech and pharmaceutical firms.
The acquisition of Avid Bioservices by GHO and Ampersand signals increased investment in the healthcare sector, potentially boosting growth and innovation in biotech, which can drive market performance.
Frequently Asked Questions About CDMO Stock
What is 's (CDMO) stock forecast for 2025?
Analyst forecasts for (CDMO) are not currently available. The stock is trading at $0.00.
Is CDMO stock a good investment in 2025?
Analyst ratings for CDMO are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CDMO stock?
Price predictions from Wall Street analysts for CDMO are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for CDMO ?
Price targets from Wall Street analysts for CDMO are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for CDMO ?
Price targets from Wall Street analysts for CDMO are not currently available. The stock is trading at $0.00.
What is the overall CDMO consensus from analysts for ?
Analyst ratings for CDMO are not currently available. The stock is trading at $0.00.
How accurate are CDMO stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
